Biotechnology company Halozyme Therapeutics Inc (NASDAQ:HALO) said on Wednesday that it has successfully filed a Biologics License Application for a subcutaneous (SC) formulation of trastuzumab (Herceptin) under the US Food and Drug Administration's (FDA) approved breast cancer indications.
Herceptin is reportedly a registered trademark of Genentech and Herceptin's BLA has been submitted by Genentech, a member of the Roche Group.
For 2017, Roche reported sales of Herceptin of CHF2.7bn in the US. Sales of subcutaneous trastuzumab will be dependent on market adoption.
This is a co-formulation with Halozyme's proprietary recombinant human hyaluronidase enzyme (ENHANZE technology), which is approved and marketed under the Herceptin SC brand in many countries outside the US.
(EUR1= CHF1.16)
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA